[Observation of therapeutic effect of single-dose combined administration of Qinghaosu, sulphomethoxine, pyrimethamine and primaquine in the treatment of chloroquine-resistant malignant malaria (author's transl)].
D000293:Adolescent; D000328:Adult; D000962:Antimalarials / Q000008:administration & dosage* / Q000009:adverse effects; D037621:Artemisinins; D002648:Child; D002675:Child, Preschool; D002738:Chloroquine / Q000008:administration & dosage; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008288:Malaria / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011319:Primaquine / Q000008:administration & dosage; D011714:Pyrans / Q000008:administration & dosage; D011739:Pyrimethamine / Q000008:administration & dosage; D012717:Sesquiterpenes; D013418:Sulfamethazine / Q000008:administration & dosage
D000962:Antimalarials; D037621:Artemisinins; D011714:Pyrans; D012717:Sesquiterpenes; D013418:Sulfamethazine; D002738:Chloroquine; C031327:artemisinin; D011319:Primaquine; D011739:Pyrimethamine